Ustekinumab beats placebo for ulcerative colitis

International trial showed subcutaneous maintenance therapy to be effective
Clare Pain
subcutaneous biologic

Patients with moderate to severe ulcerative colitis are more likely to achieve clinical remission and a range of other outcomes on ustekinumab than placebo, according to the results of a phase 3 trial.

In the pharma-company funded trial (known as UNIFI), 961 patients from 244 international sites were randomised to one of two different intravenous doses of a single, induction infusion of the drug or IV placebo.